- Home
- / PDL BioPharma
PDL BioPharma
Stock Price
$2.5
2021-01-08
Market Capitalization
$282.1 M
2021-01-08
Revenue
$54.8 M
FY, 2019
PDL BioPharma Summary
Company Summary
- Overview
- PDL BioPharma pioneered the humanization of monoclonal antibodies and, by so doing, enabled the discoveryof a new generation of targeted treatments for cancer and immunologic diseases.
- Type
- Public
- Status
- Active
- Founded
- 1986
- HQ
- Incline Village, NV, US | view all locations
- Website
- http://pdl.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Christopher Stone, Vice President and General Counsel
Ed Imbrogno, Vice President, Finance and Chief Accounting Officer
LocationsView all
1 location detected
Incline Village, NV HQ
United States
932 Southwood Blvd, Incline Village
PDL BioPharma Financials
Summary Financials
- Revenue (Q2, 2020)
- $4.1M
- Cash (FY, 2020)
- $126.8M
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026